Skip to content
S5604Senate2021-2022 SessionSame asA6431

Fund Sickle Cell Treatment Centers

Official title

“Establishes the Sickle Cell Treatment Act”

Sponsor James Sanders Jr.SD-10+13 co-sponsorsAffects Finance
Status
In Senate Committee
Finance
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Finance

What's happening

This bill establishes designated sickle cell treatment and research centers in New York and exempts sickle cell patients from certain opioid prescription restrictions.

Why it matters

  1. Creation of Specialized Centers. The bill mandates the establishment of five designated “centers for sickle cell care excellence” at hospitals or hospices, ensuring that patients have access to comprehensive, specialized care, cutting-edge research, and educational resources specific to sickle cell disease.

  2. Targeted Outpatient Support. By requiring the commissioner to designate ten outpatient treatment centers based on patient population concentrations, the bill aims to address disparities in access to care and improve disease management for individuals living with sickle cell disease, particularly in underserved areas.

  3. Dedicated Funding. Each center for excellence and outpatient center receives annual state funding ($200,000 and $100,000 respectively), supporting infrastructure, research, and ongoing care improvements—potentially accelerating advancements in treatment and patient outcomes.

  4. Opioid Prescription Flexibility. The bill exempts sickle cell patients (not in remission) from certain opioid prescribing restrictions, acknowledging the unique and severe pain associated with the disease and potentially reducing barriers to effective pain management.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Fund Sickle Cell Treatment Centers

Plain English, a few words. Used as the page title.

Sponsors

History

  1. Reported and committed to finance
  2. Referred to health
  3. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A6431Assembly

Fund Sickle Cell Treatment Centers

In Assembly Committee · Ways And Means · Sponsor Alicia Hyndman

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

5604

2021-2022 Regular Sessions

IN SENATE

March 12, 2021

Introduced by Sen. SANDERS -- read twice and ordered printed, and when printed to be committed to the Committee on Health

AN ACT to amend the public health law, in relation to establishing the "Sickle Cell Treatment Act"; and making an appropriation therefor

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. This act shall be known and may be cited as the "Sickle Cell Treatment Act".

§ 2. The public health law is amended by adding a new section 2807-aa to read as follows:

§ 2807-aa. Sickle cell centers for excellence and outpatient treatment centers. 1. Centers for sickle cell care excellence. The commissioner shall designate five general hospitals or hospices under article forty of this chapter, upon successful application, as centers for sickle cell care excellence. The designations shall be made through an application designed by the department, and based on service, staffing and other criteria as developed by the commissioner. The centers of excellence shall provide specialized sickle cell disease care, treatment, palliative care, education and related services and shall conduct specialized research into the care, treatment and management of sickle cell disease. Designation as a center for sickle cell care excellence shall not entitle a center to enhanced reimbursement, but may be utilized in outreach and other promotional activities. Each center for sickle cell care excellence shall affiliate and cooperate with major centers of higher learning, including medical colleges, and life science research institutes in the state. The state university shall enter into appropriate legal agreements to enable this cooperation. Each center for sickle cell care excellence shall receive two hundred thousand dollars per year from the department, from amounts appropriated for that purpose, to be used on sickle cell disease research.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD08525-01-1

S. 5604 2

2. Outpatient treatment centers. The commissioner shall designate ten hospitals, distributed based on sickle cell patient population concentrations, as sickle cell outpatient treatment centers which shall provide patients treatment for sickle cell disease as an outpatient. Each sickle cell outpatient treatment center shall receive one hundred thousand dollars per year from the department, from amounts appropriated for that purpose, to be used to ensure the proper management and equipping of the centers to care for sickle cell patients.

§ 3. Subdivision 8 of section 3331 of the public health law, as added by section 7-a of part D of chapter 57 of the laws of 2018, is amended to read as follows:

8. No opioids shall be prescribed to a patient initiating or being maintained on opioid treatment for pain which has lasted more than three months or past the time of normal tissue healing, unless the medical record contains a written treatment plan that follows generally accepted national professional or governmental guidelines. The requirements of this paragraph shall not apply in the case of patients who are being treated for cancer or sickle cell disease that is not in remission, who are in hospice or other end-of-life care, or whose pain is being treated as part of palliative care practices.

§ 4. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public health law, in relation to establishing the "Sickle Cell Treatment Act"; and making an appropriation therefor

Purpose

Establishes the Sickle Cell Treatment Act

Summary of specific provisions

Section 1 of the bill would set forth that this act shall be known and may be cited as the "Sickle Cell Treatment Act".

Section 2 amends the public health law by adding a new section 2807-aa which mandates the Commissioner of the Department of Health to designate Sickle cell centers for excellence and outpatient treatment centers.

Section 3 amends subdivision 8 of section 3331 of the public health law, as added by section 7-a of part D of chapter 57 of the laws of 2018 relating to opioid exemption.

Section 4 provides the effective date.

Justification

Sickle Cell patients experience a multitude of symptoms that can range from mild to severe. There is little to no awareness of possible ways to manage these symptoms, which is why centers for excellence (COE), and outpatient treatment centers are essential.

The Centers of Excellence would serve as a hub for adults and children alike to have access to professionals that can understand, monitor, and provide care in the most effective way possible. The COEs would further serve as leaders to other institutions in the treatment of SCD and would establish the best practices that could then be used in other healthcare facilities around the state.

Outpatient hospitals would help reduce the need of sickle cell patients to check into the emergency room for pain, which is the traditional response of people who are suffering an SCD pain crisis. Patients would have access to readily available services that are designated to help specifically with SCD pain management and symptoms because outpatient services would be available in areas where there is sufficient need for the service. The reduced burden on emergency rooms, especially in times of health crisis, can help patients and doctors alike.

Pain is a major symptom of Sickle Cell disease (SCD) and one of the principal reasons that people with SCD go to the emergency room.. Pain experienced by sickle cell patients manifests itself as abrupt and very debilitating pain in any part of the body. Individuals diagnosed with sickle cell can begin having pain crises as early as 6 months of age. This legislation will allow certain sickle cell patients to easily gain access to opioid therapy. Currently, sickle cell patients are restricted in being treated with opioids. However, due to the debilitating pain

sickle cell disease patients encounter during crisis, opioid therapy serves to reduce the pain that patients experience.

Legislative history

This is a new bill.

Fiscal implications

To be determined

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.